Pedersoli Studio Legale advised the Lonza Group, a multinational company listed on Zurich Stock Exchange and global leader in pharmaceutical, biotech and nutrition development and manufacturing, in the acquisition of a business unit from Exosomics, a company specialising, inter alia, in the extraction, enrichment, isolation and characterisation of exosomes and other extracellular vesicles.
The agreement includes the acquisition of staff and assets of Exosomics belonging to the said business unit and relevant laboratories, located in Siena.
Lonza is a minority shareholder of Exosomics since 2017 and it shall remain part of the corporate structure following the consummation of the transaction.
As a result of the acquisition of Exosomics business unit, Lonza shall access resources and know-how in the field of extracellular vesicle characterisation. In addition to R&D, Lonza shall extend its offer in the industry of exosomes, further strengthening its global leadership as CDMO (Contract Development and Manufacturing Organization) in the reference sector.
Pedersoli advised the purchaser with a cross-practice team led by Ascanio Cibrario (equity partner) and including Giacomo Massironi (associate), as to corporate M&A aspects, while Andrea de’ Mozzi (equity partner) provided assistance in relation to tax aspects. Labour law matters have been managed by Andrea Scarpellini (senior associate).